Hepatitis B

WHO welcomes global momentum on viral hepatitis

On World Hepatitis Day, 28 July, WHO welcomes new progress in tackling one of the world’s most serious diseases. Viral hepatitis – a group of infectious diseases known as hepatitis A, B, C, D, and E – affects millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year.
“For years, viral hepatitis has been largely neglected,” says Dr Margaret Chan, Director-General at WHO. “But now we are beginning to see greater awareness and global momentum building to tackle it.”

WHO in the Western Pacific: Working towards a hepatitis-free Region

Viral hepatitis causes an estimated 1.4 million deaths worldwide each year—which is close to the number of deaths caused by HIV/AIDS, and more than those caused by malaria and tuberculosis. Despite the high burden on individuals, families and societies, political and financial engagement remains inadequate. The World Health Organization (WHO) estimates that more than 500 million people worldwide are affected by chronic hepatitis B and C.

USA: une étude confirme l'innocuité des vaccins

Les vaccins utilisés de façon routinière aux Etats-Unis chez les enfants contre différentes infections sont sûrs et ne sont pas liés à l'autisme ou à la leucémie, ne provoquant que très rarement des réactions graves, selon une étude publiée mardi.
En 2011, l'Institut de Médecine aux Etats-Unis (IOM) avait publié un rapport qui faisait l'unanimité du corps médical et concluait déjà à l'innocuité des vaccinations. 

GAVI responds to Médecins Sans Frontières and civil society organisations’ open letter

The GAVI Alliance shares recently published MSF concerns about the slow implementation of the WHO recommendation to deliver a dose of hepatitis B vaccine immediately after birth.
WHO estimates that hepatitis B causes around 260,000 deaths each year in GAVI-eligible countries, mostly in older men. Thanks to GAVI’s support for infant hepatitis B vaccination since 2000 – now included in the pentavalent vaccine and in routine use in 72 of 73 GAVI-supported countries – this number is expected to fall significantly in the future.

GAVI Alliance addresses MSF concerns on infant Hepatitis B vaccine

Medecins Sans Frontieres recently expressed concern about the slow implementation of the World Health Organization’s recommendation that a dose of hepatitis B vaccine be delivered immediately after birth.
Since 2000, the GAVI Alliance has supported infant hepatitis B vaccinations in nearly all GAVI-supported countries. Hepatitis B causes around 260,000 deaths each year in GAVI-eligible countries, according to the World Health Organization.

GSK offers five-year price freeze on vaccines for GAVI graduating countries

GlaxoSmithKline announced on May 20 that it will support developing countries that have growing economies by putting a five year freeze on vaccine prices for countries who graduate from GAVI Alliance support.
The announcement was made by Andrew Witty, the CEO of GSK, at the GAVI Alliance replenishment launch meeting in Brussels.

CIA Announces Plans To End Fake Vaccination Programs

The White House announced that the CIA will stop using fake vaccination programs to further its spy operations. The decision comes after leaders from U.S. public health schools brought the practice to light.

Listen to the audio version of this story here.


Senegal: Hepatitis B - a Silent Emergency in Senegal

More than two million people in Senegal, or some 15 percent of the population, including 350,000 chronic carriers, have hepatitis B as a result of untimely vaccinations, prohibitive treatment costs and lack of universal screening to curb transmissions.
"It's quite an urgent public health concern," said Mamadou Mourtalla Ka, dean of the Thies School of Medicine in Senegal and a viral hepatitis and liver cancer researcher. "Hepatitis B is much more common than people think and causes many illnesses, many deaths here each year."

Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization

Sanofi Pasteur, the vaccines division of Sanofi, announced today that its pediatric pentavalent vaccine Shan5(TM), developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, India, has received prequalification status from the World Health Organization (WHO). This status is based on a review of a comprehensive set of data related to the process and the product characteristics, as well as on a positive recommendation of WHO’s auditors following a site inspection of Shantha’s manufacturing facilities.